# A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT00112060** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Spectrum Pharmaceuticals, Inc**

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** PT-523 for Injection

## Key facts

- **NCT ID:** NCT00112060
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-04
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112060, "A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00112060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*